0001193125-22-002665.txt : 20220105 0001193125-22-002665.hdr.sgml : 20220105 20220105161605 ACCESSION NUMBER: 0001193125-22-002665 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211231 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220105 DATE AS OF CHANGE: 20220105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Regulus Therapeutics Inc. CENTRAL INDEX KEY: 0001505512 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264738379 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35670 FILM NUMBER: 22511334 BUSINESS ADDRESS: STREET 1: 4224 CAMPUS POINT COURT STREET 2: SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-202-6300 MAIL ADDRESS: STREET 1: 4224 CAMPUS POINT COURT STREET 2: SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 d277160d8k.htm 8-K 8-K
false 0001505512 0001505512 2021-12-31 2021-12-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 31, 2021

 

 

Regulus Therapeutics Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-35670   26-4738379

(State of

incorporation)

  

(Commission

File No.)

  

(IRS Employer

Identification No.)

 

4224 Campus Point Court, Suite 210

San Diego, CA

   92121
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (858) 202-6300

N/A

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   RGLS   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 1.01

Entry into a Material Definitive Agreement.

Eleventh Amendment to Loan and Security Agreement

On December 31, 2021, Regulus Therapeutics Inc. (the “Company”) entered into an eleventh amendment to its Loan and Security Agreement (the “Eleventh Amendment”) with Oxford Finance LLC, as the collateral agent and a lender (the “Lender”), dated June 17, 2016, as amended, pursuant to which the Lender lent the Company $20.0 million in a term loan (“Term Loan”).

Under the terms of the Eleventh Amendment, the Company’s required monthly payments to the Lender are to be comprised of interest only through and including (i) December 1, 2022, if the 2022 Equity Event (as defined below) does not occur or (ii) December 1, 2023 if the 2022 Equity Event occurs. The “2022 Equity Event” means the receipt by the Company, during the calendar year 2022, of unrestricted net cash proceeds of at least $20.0 million from the sale and issuance of its equity securities. In addition, the maturity date for the Term Loan was extended to May 1, 2024.

If the 2022 Equity Event does not occur, then commencing on January 1, 2023 and continuing on each successive payment date thereafter through and including the maturity date of May 1, 2024, the Company will be required to make consecutive equal monthly payments of principal, together with applicable interest, in arrears, to the Lender.

If the 2022 Equity Event does occur, then commencing on January 1, 2024 and continuing on each successive payment date thereafter through and including the maturity date of May 1, 2024, the Company will be required to make consecutive equal monthly payments of principal, together with applicable interest, in arrears, to the Lender.

The Eleventh Amendment also provides that the Company is required to maintain cash in a collateral account controlled by the Lender of $5.0 million. As consideration for the Lender’s entry into the Eleventh Amendment, the Company made a payment of $291,000 to the Lender.

The foregoing summary is qualified in its entirety by the full text of the Eleventh Amendment, a copy of which is filed as Exhibit 10.1 to this report.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

10.1    Eleventh Amendment to Loan and Security Agreement, dated December 31, 2021, by and between the Company and Oxford Finance LLC.
104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Regulus Therapeutics Inc.
Date: January 5, 2022     By:  

/s/ Joseph P. Hagan

      Joseph P. Hagan
      President and Chief Executive Officer
 EX-10.1 2 d277160dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

ELEVENTH AMENDMENT TO THE LOAN AND SECURITY AGREEMENT

THIS ELEVENTH AMENDMENT TO THE LOAN AND SECURITY AGREEMENT (this “Amendment”) is made effective as of December 31, 2021 (the “Amendment Date”) by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (in its individual capacity, “Oxford”; and in its capacity as Collateral Agent, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”) and REGULUS THERAPEUTICS INC., a Delaware corporation with offices located at 4224 Campus Point Court, Suite 210, San Diego, CA 92121 (“Borrower”).

WHEREAS, Collateral Agent, Borrower and Lenders party thereto from time to time have entered into that certain Loan and Security Agreement, dated as of June 17, 2016 (as amended, supplemented or otherwise modified from time to time, the “Loan Agreement”), pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof; and

WHEREAS, Borrower, Lenders and Collateral Agent desire to amend certain provisions of the Loan Agreement as provided herein and subject to the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:

 

  1.

Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement

 

  2.

Section 13.1 of the Loan Agreement is hereby amended by amending and restating the following definitions therein as follows:

“Second Amortization Date” is (i) January 1, 2023, if the 2022 Equity Event does not occur and (ii) January 1, 2024, if the 2022 Equity Event occurs.

“Maturity Date” is May 1, 2024.

“Minimum Cash Balance” is Five Million Dollars ($5,000,000.00).

 

  3.

Section 13.1 of the Loan Agreement is hereby further amended by adding the following definition therein in alphabetical order:

“2022 Equity Event” is the receipt by Borrower, during the calendar year 2022, of unrestricted net cash proceeds of at least Twenty Million Dollars ($20,000,000.00) from the sale and issuance of its equity securities.

 

  4.

The Amortization Table attached to the Disbursement Letter dated as of the Effective Date is amended and restated as set forth on the Amortization Table attached as Exhibit A hereto effective upon the occurrence of the Principal Paydown Event.

 

  5.

Limitation of Amendment.

 

  a.

The amendments set forth above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.

  b.

This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect.

 

  6.

To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:

 

  a.

Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;

 

  b.

Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;

 

  c.

The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;

 

  d.

The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (i) any law or regulation binding on or affecting Borrower, (ii) any contractual restriction with a Person binding on Borrower, (iii) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower;

 

  e.

The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made;

 

  f.

This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights; and

 

  g.

The Borrower hereby remises, releases, acquits, satisfies and forever discharges the Lenders and Collateral Agent, their agents, employees, officers, directors, predecessors, attorneys and all others acting or purporting to act on behalf of or at the direction of the Lenders and Collateral Agent (“Releasees”), of and from any and all manner of actions, causes of action, suit, debts, accounts, covenants, contracts, controversies, agreements, variances, damages, judgments, claims and demands whatsoever, in law or in equity, which any of such parties ever had, now has or, to the extent arising from or in connection with any act, omission or state of facts taken or existing on or prior to the date hereof, may have after the date hereof against the Releasees, for, upon or by reason of any matter, cause or thing whatsoever relating to or arising out of the Loan Agreement or the other Loan Documents on or prior to the date hereof through the date hereof. Without limiting the generality of the foregoing, the Borrower waives and affirmatively agrees not to allege or otherwise pursue any defenses, affirmative defenses, counterclaims, claims, causes of action, setoffs or other rights they do, shall or may have as of the date hereof, including the rights to

 

2

  contest: (a) the right of Collateral Agent and each Lender to exercise its rights and remedies described in the Loan Documents; (b) any provision of this Amendment or the Loan Documents; or (c) any conduct of the Lenders or other Releasees relating to or arising out of the Loan Agreement or the other Loan Documents on or prior to the date hereof.

 

  7.

Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.

 

  8.

Borrower agrees to promptly pay (but in no event in less than 5 Business Days of invoice date) all unpaid Lenders’ Expenses incurred through the date hereof, which may be debited (or ACH’d) from any of Borrower’s accounts.

 

  9.

This Amendment shall be deemed effective as of the Amendment Date upon the due execution and delivery to Collateral Agent of this Amendment by each party hereto and the payment by Borrower of an amendment fee to Collateral Agent in the amount of Two Hundred Ninety One Thousand Dollars ($291,000.00).

 

  10.

This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.

 

  11.

This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of California.

[Balance of Page Intentionally Left Blank – Signature Pages to Follow]

 

3

IN WITNESS WHEREOF, the parties hereto have caused this Eleventh Amendment to Loan and Security Agreement to be executed as of the date first set forth above.

 

BORROWER:
REGULUS THERAPEUTICS INC.
By   /s/ Cris Calsada
Name:   Cris Calsada
Title:   Chief Financial Officer

 

COLLATERAL AGENT AND LENDER:
OXFORD FINANCE LLC
By   /s/ Colette H. Featherly
Name:   Colette H. Featherly
Title:   Senior Vice President

EXHIBIT A

Amortization Table

Please see attached.

Oxford Finance LLC

Amortization Table

Regulus Total

 

Start Date:

      6/22/2016         Disclaimer:

Interest Rate:

      8.97885 %        THIS IS A STANDARD AMORTIZATION SCHEDULE. IT IS NOT INTENDED TO BE USED FOR PAYOFF PURPOSES.

Term:

      47      23 IO + 24 PI    

Payment:

      Varies     

Final Payment:

    $ 457,809.27      5.50%   

3rd Amendment Fee:

    $ 25,000.00        

Fifth Amendment Fee:

    $ 25,000.00        

Sixth Amendment Fee:

    $ 17,000.00        

Seventh Amendment Fee:

    $ 15,000.00        

Eighth Amendment Fee:

    $ 650,000.00        

Second IO Extension Fee

    $ 115,000.00        

Amount:

      20,000,000.00         THIS AMORTIZATION SCHEDULE REPRESENTS A FLOATING INTEREST RATE LOAN. INTEREST RATE CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT

Interim Interest Days:

      9     

Interim Interest:

    $ 44,894.25     
     
     

 

PMT
No.

   Payment
Date		     Beginning
Balance		     Monthly
Payment		     Interest      Principal      Ending
Balance		  
    7/1/16       Interim Interest Due      $ 20,000,000.00  
1     8/1/16     $ 20,000,000.00     $ 154,635.75     $ 154,635.75      $ 0.00      $ 20,000,000.00  
2     9/1/16     $ 20,000,000.00     $ 154,635.75     $ 154,635.75      $ 0.00      $ 20,000,000.00  
3     10/1/16     $ 20,000,000.00     $ 149,647.50     $ 149,647.50      $ 0.00      $ 20,000,000.00  
4     11/1/16     $ 20,000,000.00     $ 154,635.75     $ 154,635.75      $ 0.00      $ 20,000,000.00  
5     12/1/16     $ 20,000,000.00     $ 149,647.50     $ 149,647.50      $ 0.00      $ 20,000,000.00  
6     1/1/17     $ 20,000,000.00     $ 154,635.75     $ 154,635.75      $ 0.00      $ 20,000,000.00  
7     2/1/17     $ 20,000,000.00     $ 154,635.75     $ 154,635.75      $ 0.00      $ 20,000,000.00  
8     3/1/17     $ 20,000,000.00     $ 139,671.00     $ 139,671.00      $ 0.00      $ 20,000,000.00  
9     4/1/17     $ 20,000,000.00     $ 154,635.75     $ 154,635.75      $ 0.00      $ 20,000,000.00  
10     5/1/17     $ 20,000,000.00     $ 149,647.50     $ 149,647.50      $ 0.00      $ 20,000,000.00  
11     6/1/17     $ 20,000,000.00     $ 154,635.75     $ 154,635.75      $ 0.00      $ 20,000,000.00  
12     7/1/17     $ 20,000,000.00     $ 149,647.50     $ 149,647.50      $ 0.00      $ 20,000,000.00  
13     8/1/17     $ 20,000,000.00     $ 154,635.75     $ 154,635.75      $ 0.00      $ 20,000,000.00  
14     9/1/17     $ 20,000,000.00     $ 154,635.75     $ 154,635.75      $ 0.00      $ 20,000,000.00  
15     10/1/17     $ 20,000,000.00     $ 149,647.50     $ 149,647.50      $ 0.00      $ 20,000,000.00  
16     11/1/17     $ 20,000,000.00     $ 154,635.75     $ 154,635.75      $ 0.00      $ 20,000,000.00  
17     12/1/17     $ 20,000,000.00     $ 149,647.50     $ 149,647.50      $ 0.00      $ 20,000,000.00  
18     1/1/18     $ 20,000,000.00     $ 154,635.75     $ 154,635.75      $ 0.00      $ 20,000,000.00  
19     2/1/18     $ 20,000,000.00     $ 154,635.75     $ 154,635.75      $ 0.00      $ 20,000,000.00  
20     3/1/18     $ 20,000,000.00     $ 139,671.00     $ 139,671.00      $ 0.00      $ 20,000,000.00  
21     4/1/18     $ 20,000,000.00     $ 154,635.75     $ 154,635.75      $ 0.00      $ 20,000,000.00  
22     5/1/18     $ 20,000,000.00     $ 149,647.50     $ 149,647.50      $ 0.00      $ 20,000,000.00  
23     6/1/18     $ 20,000,000.00     $ 154,635.75     $ 154,635.75      $ 0.00      $ 20,000,000.00  
24     7/1/18     $ 20,000,000.00     $ 982,980.83     $ 149,647.50      $ 833,333.33      $ 19,166,666.67  
25     8/1/18     $ 19,166,666.67     $ 148,192.59     $ 148,192.59      $ 0.00      $ 19,166,666.67  
26     9/1/18     $ 19,166,666.67     $ 148,192.59     $ 148,192.59      $ 0.00      $ 19,166,666.67  
27     10/1/18     $ 19,166,666.67     $ 143,412.19     $ 143,412.19      $ 0.00      $ 19,166,666.67  
28     11/1/18     $ 19,166,666.67     $ 1,106,525.93     $ 148,192.59      $ 958,333.33      $ 18,208,333.33  
29     12/1/18     $ 18,208,333.33     $ 1,686,680.17     $ 136,241.58      $ 1,550,438.60      $ 16,657,894.74  
30     1/1/19     $ 16,657,894.74     $ 1,054,233.90     $ 128,795.30      $ 925,438.60      $ 15,732,456.14  
31     2/1/19     $ 15,732,456.14     $ 121,640.01     $ 121,640.01      $ 0.00      $ 15,732,456.14  
32     3/1/19     $ 15,732,456.14     $ 109,868.39     $ 109,868.39      $ 0.00      $ 15,732,456.14  
33     4/1/19     $ 15,732,456.14     $ 560,335.01     $ 121,640.01      $ 438,695.00      $ 15,293,761.14  
34     5/1/19     $ 15,293,761.14     $ 726,933.66     $ 114,433.66      $ 612,500.00      $ 14,681,261.14  
35     6/1/19     $ 14,681,261.14     $ 113,512.39     $ 113,512.39      $ 0.00      $ 14,681,261.14  
36     7/1/19     $ 14,681,261.14     $ 109,850.70     $ 109,850.70      $ 0.00      $ 14,681,261.14  
37     8/1/19     $ 14,681,261.14     $ 113,512.39     $ 113,512.39      $ 0.00      $ 14,681,261.14  
38     9/1/19     $ 14,681,261.14     $ 113,512.39     $ 113,512.39      $ 0.00      $ 14,681,261.14  
39     10/1/19     $ 14,681,261.14     $ 109,850.70     $ 109,850.70      $ 0.00      $ 14,681,261.14  
40     11/1/19     $ 14,681,261.14     $ 113,512.39     $ 113,512.39      $ 0.00      $ 14,681,261.14  
41     12/1/19     $ 14,681,261.14     $ 109,850.70     $ 109,850.70      $ 0.00      $ 14,681,261.14  
42     1/1/20     $ 14,681,261.14     $ 113,512.39     $ 113,512.39      $ 0.00      $ 14,681,261.14  
43     2/1/20     $ 14,681,261.14     $ 113,512.39     $ 113,512.39      $ 0.00      $ 14,681,261.14  
44     3/1/20     $ 14,681,261.14     $ 106,189.01     $ 106,189.01      $ 0.00      $ 14,681,261.14  
45     4/1/20     $ 14,681,261.14     $ 113,512.39     $ 113,512.39      $ 0.00      $ 14,681,261.14  
46     5/1/20     $ 14,681,261.14     $ 109,850.70     $ 109,850.70      $ 0.00      $ 14,681,261.14  
47     6/1/20     $ 14,681,261.14     $ 113,512.39     $ 113,512.39      $ 0.00      $ 14,681,261.14  
48     7/1/20     $ 14,681,261.14     $ 109,850.70     $ 109,850.70      $ 0.00      $ 14,681,261.14  
49     8/1/20     $ 14,681,261.14     $ 113,512.39     $ 113,512.39      $ 0.00      $ 14,681,261.14  
50     9/1/20     $ 14,681,261.14     $ 113,512.39     $ 113,512.39      $ 0.00      $ 14,681,261.14  
51     10/1/20     $ 14,681,261.14     $ 1,109,850.70     $ 109,850.70      $ 1,000,000.00      $ 13,681,261.14  
52     11/1/20     $ 13,681,261.14     $ 4,105,780.60     $ 105,780.60      $ 4,000,000.00      $ 9,681,261.14  
53     12/1/20     $ 9,681,261.14     $ 5,072,438.83     $ 72,438.83      $ 5,000,000.00      $ 4,681,261.14  
54     1/1/21     $ 4,681,261.14     $ 36,194.52     $ 36,194.52      $ 0.00      $ 4,681,261.14  
55     2/1/21     $ 4,681,261.14     $ 36,194.52     $ 36,194.52      $ 0.00      $ 4,681,261.14  
56     3/1/21     $ 4,681,261.14     $ 32,691.82     $ 32,691.82      $ 0.00      $ 4,681,261.14  
57     4/1/21     $ 4,681,261.14     $ 36,194.52     $ 36,194.52      $ 0.00      $ 4,681,261.14  
58     5/1/21     $ 4,681,261.14     $ 35,026.95     $ 35,026.95      $ 0.00      $ 4,681,261.14  
59     6/1/21     $ 4,681,261.14     $ 36,194.52     $ 36,194.52      $ 0.00      $ 4,681,261.14  
60     7/1/21     $ 4,681,261.14     $ 35,026.95     $ 35,026.95      $ 0.00      $ 4,681,261.14  
61     8/1/21     $ 4,681,261.14     $ 36,194.52     $ 36,194.52      $ 0.00      $ 4,681,261.14  
62     9/1/21     $ 4,681,261.14     $ 36,194.52     $ 36,194.52      $ 0.00      $ 4,681,261.14  
63     10/1/21     $ 4,681,261.14     $ 35,026.95     $ 35,026.95      $ 0.00      $ 4,681,261.14  
64     11/1/21     $ 4,681,261.14     $ 36,194.52     $ 36,194.52      $ 0.00      $ 4,681,261.14  
65     12/1/21     $ 4,681,261.14     $ 35,026.95     $ 35,026.95      $ 0.00      $ 4,681,261.14  
66     1/1/22     $ 4,681,261.14     $ 36,194.52     $ 36,194.52      $ 0.00      $ 4,681,261.14  
67     2/1/22     $ 4,681,261.14     $ 36,194.52     $ 36,194.52      $ 0.00      $ 4,681,261.14  
68     3/1/22     $ 4,681,261.14     $ 32,691.82     $ 32,691.82      $ 0.00      $ 4,681,261.14  
69     4/1/22     $ 4,681,261.14     $ 36,194.52     $ 36,194.52      $ 0.00      $ 4,681,261.14  
70     5/1/22     $ 4,681,261.14     $ 35,026.95     $ 35,026.95      $ 0.00      $ 4,681,261.14  
71     6/1/22     $ 4,681,261.14     $ 36,194.52     $ 36,194.52      $ 0.00      $ 4,681,261.14  
72     7/1/22     $ 4,681,261.14     $ 35,026.95     $ 35,026.95      $ 0.00      $ 4,681,261.14  
73     8/1/22     $ 4,681,261.14     $ 36,194.52     $ 36,194.52      $ 0.00      $ 4,681,261.14  
74     9/1/22     $ 4,681,261.14     $ 36,194.52     $ 36,194.52      $ 0.00      $ 4,681,261.14  
75     10/1/22     $ 4,681,261.14     $ 35,026.95     $ 35,026.95      $ 0.00      $ 4,681,261.14  
76     11/1/22     $ 4,681,261.14     $ 36,194.52     $ 36,194.52      $ 0.00      $ 4,681,261.14  
77     12/1/22     $ 4,681,261.14     $ 35,026.95     $ 35,026.95      $ 0.00      $ 4,681,261.14  
78     1/1/23     $ 4,681,261.14     $ 311,562.82     $ 36,194.52      $ 275,368.30      $ 4,405,892.84  
79     2/1/23     $ 4,405,892.84     $ 309,433.73     $ 34,065.43      $ 275,368.30      $ 4,130,524.54  
80     3/1/23     $ 4,130,524.54     $ 304,214.03     $ 28,845.72      $ 275,368.30      $ 3,855,156.23  
81     4/1/23     $ 3,855,156.23     $ 305,175.55     $ 29,807.25      $ 275,368.30      $ 3,579,787.93  
82     5/1/23     $ 3,579,787.93     $ 302,153.62     $ 26,785.32      $ 275,368.30      $ 3,304,419.63  
83     6/1/23     $ 3,304,419.63     $ 300,917.37     $ 25,549.07      $ 275,368.30      $ 3,029,051.33  
84     7/1/23     $ 3,029,051.33     $ 298,032.80     $ 22,664.50      $ 275,368.30      $ 2,753,683.02  
85     8/1/23     $ 2,753,683.02     $ 296,659.19     $ 21,290.89      $ 275,368.30      $ 2,478,314.72  
86     9/1/23     $ 2,478,314.72     $ 294,530.11     $ 19,161.80      $ 275,368.30      $ 2,202,946.42  
87     10/1/23     $ 2,202,946.42     $ 291,851.57     $ 16,483.27      $ 275,368.30      $ 1,927,578.12  
88     11/1/23     $ 1,927,578.12     $ 290,271.93     $ 14,903.62      $ 275,368.30      $ 1,652,209.81  
89     12/1/23     $ 1,652,209.81     $ 287,730.76     $ 12,362.45      $ 275,368.30      $ 1,376,841.51  
90     1/1/24     $ 1,376,841.51     $ 286,013.75     $ 10,645.45      $ 275,368.30      $ 1,101,473.21  
91     2/1/24     $ 1,101,473.21     $ 283,884.66     $ 8,516.36      $ 275,368.30      $ 826,104.91  
92     3/1/24     $ 826,104.91     $ 281,343.49     $ 5,975.19      $ 275,368.30      $ 550,736.60  
93     4/1/24     $ 550,736.60     $ 279,626.48     $ 4,258.18      $ 275,368.30      $ 275,368.30  
94     5/1/24     $ 275,368.30     $ 277,428.71     $ 2,060.41      $ 275,368.30      $ 0.00  
Final     5/1/24       Final Payment     $ 1,304,809.27     $ 1,304,809.27      $ 0.00     
     

 

 

    

 

 

     

 

 

     
      Totals     $ 29,517,369.15     $ 9,517,369.15      $ 20,000,000.00     
     

 

 

    

 

 

     

 

 

     

Oxford Finance LLC

Amortization Table

Regulus Total

 

Start Date:

      6/22/2016        

Disclaimer:

Interest Rate:

      8.97885 %        THIS IS A STANDARD AMORTIZATION SCHEDULE. IT IS NOT INTENDED TO BE USED FOR PAYOFF PURPOSES.

Term:

      47      23 IO + 24 PI   

Payment:

      Varies     

Final Payment:

    $ 457,809.27      5.50%   

3rd Amendment Fee:

    $ 25,000.00        

Fifth Amendment Fee:

    $ 25,000.00        

Sixth Amendment Fee:

    $ 17,000.00        

Seventh Amendment Fee:

    $ 15,000.00        

Eighth Amendment Fee:

    $ 650,000.00        

Second IO Extension Fee

    $ 115,000.00        

Amount:

      20,000,000.00         THIS AMORTIZATION SCHEDULE REPRESENTS A FLOATING INTEREST RATE LOAN. INTEREST RATE CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT

Interim Interest Days:

      9     

Interim Interest:

    $ 44,894.25     
     
     

 

PMT

No.

   Payment
Date		   Beginning
Balance		     Monthly
Payment		     Interest     Principal     Ending
Balance		  
  7/1/16       Interim Interest Due       $ 20,000,000.00  
1   8/1/16   $ 20,000,000.00     $ 154,635.75     $ 154,635.75     $ 0.00     $ 20,000,000.00  
2   9/1/16   $ 20,000,000.00     $ 154,635.75     $ 154,635.75     $ 0.00     $ 20,000,000.00  
3   10/1/16   $ 20,000,000.00     $ 149,647.50     $ 149,647.50     $ 0.00     $ 20,000,000.00  
4   11/1/16   $ 20,000,000.00     $ 154,635.75     $ 154,635.75     $ 0.00     $ 20,000,000.00  
5   12/1/16   $ 20,000,000.00     $ 149,647.50     $ 149,647.50     $ 0.00     $ 20,000,000.00  
6   1/1/17   $ 20,000,000.00     $ 154,635.75     $ 154,635.75     $ 0.00     $ 20,000,000.00  
7   2/1/17   $ 20,000,000.00     $ 154,635.75     $ 154,635.75     $ 0.00     $ 20,000,000.00  
8   3/1/17   $ 20,000,000.00     $ 139,671.00     $ 139,671.00     $ 0.00     $ 20,000,000.00  
9   4/1/17   $ 20,000,000.00     $ 154,635.75     $ 154,635.75     $ 0.00     $ 20,000,000.00  
10   5/1/17   $ 20,000,000.00     $ 149,647.50     $ 149,647.50     $ 0.00     $ 20,000,000.00  
11   6/1/17   $ 20,000,000.00     $ 154,635.75     $ 154,635.75     $ 0.00     $ 20,000,000.00  
12   7/1/17   $ 20,000,000.00     $ 149,647.50     $ 149,647.50     $ 0.00     $ 20,000,000.00  
13   8/1/17   $ 20,000,000.00     $ 154,635.75     $ 154,635.75     $ 0.00     $ 20,000,000.00  
14   9/1/17   $ 20,000,000.00     $ 154,635.75     $ 154,635.75     $ 0.00     $ 20,000,000.00  
15   10/1/17   $ 20,000,000.00     $ 149,647.50     $ 149,647.50     $ 0.00     $ 20,000,000.00  
16   11/1/17   $ 20,000,000.00     $ 154,635.75     $ 154,635.75     $ 0.00     $ 20,000,000.00  
17   12/1/17   $ 20,000,000.00     $ 149,647.50     $ 149,647.50     $ 0.00     $ 20,000,000.00  
18   1/1/18   $ 20,000,000.00     $ 154,635.75     $ 154,635.75     $ 0.00     $ 20,000,000.00  
19   2/1/18   $ 20,000,000.00     $ 154,635.75     $ 154,635.75     $ 0.00     $ 20,000,000.00  
20   3/1/18   $ 20,000,000.00     $ 139,671.00     $ 139,671.00     $ 0.00     $ 20,000,000.00  
21   4/1/18   $ 20,000,000.00     $ 154,635.75     $ 154,635.75     $ 0.00     $ 20,000,000.00  
22   5/1/18   $ 20,000,000.00     $ 149,647.50     $ 149,647.50     $ 0.00     $ 20,000,000.00  
23   6/1/18   $ 20,000,000.00     $ 154,635.75     $ 154,635.75     $ 0.00     $ 20,000,000.00  
24   7/1/18   $ 20,000,000.00     $ 982,980.83     $ 149,647.50     $ 833,333.33     $ 19,166,666.67  
25   8/1/18   $ 19,166,666.67     $ 148,192.59     $ 148,192.59     $ 0.00     $ 19,166,666.67  
26   9/1/18   $ 19,166,666.67     $ 148,192.59     $ 148,192.59     $ 0.00     $ 19,166,666.67  
27   10/1/18   $ 19,166,666.67     $ 143,412.19     $ 143,412.19     $ 0.00     $ 19,166,666.67  
28   11/1/18   $ 19,166,666.67     $ 1,106,525.93     $ 148,192.59     $ 958,333.33     $ 18,208,333.33  
29   12/1/18   $ 18,208,333.33     $ 1,686,680.17     $ 136,241.58     $ 1,550,438.60     $ 16,657,894.74  
30   1/1/19   $ 16,657,894.74     $ 1,054,233.90     $ 128,795.30     $ 925,438.60     $ 15,732,456.14  
31   2/1/19   $ 15,732,456.14     $ 121,640.01     $ 121,640.01     $ 0.00     $ 15,732,456.14  
32   3/1/19   $ 15,732,456.14     $ 109,868.39     $ 109,868.39     $ 0.00     $ 15,732,456.14  
33   4/1/19   $ 15,732,456.14     $ 560,335.01     $ 121,640.01     $ 438,695.00     $ 15,293,761.14  
34   5/1/19   $ 15,293,761.14     $ 726,933.66     $ 114,433.66     $ 612,500.00     $ 14,681,261.14  
35   6/1/19   $ 14,681,261.14     $ 113,512.39     $ 113,512.39     $ 0.00     $ 14,681,261.14  
36   7/1/19   $ 14,681,261.14     $ 109,850.70     $ 109,850.70     $ 0.00     $ 14,681,261.14  
37   8/1/19   $ 14,681,261.14     $ 113,512.39     $ 113,512.39     $ 0.00     $ 14,681,261.14  
38   9/1/19   $ 14,681,261.14     $ 113,512.39     $ 113,512.39     $ 0.00     $ 14,681,261.14  
39   10/1/19   $ 14,681,261.14     $ 109,850.70     $ 109,850.70     $ 0.00     $ 14,681,261.14  
40   11/1/19   $ 14,681,261.14     $ 113,512.39     $ 113,512.39     $ 0.00     $ 14,681,261.14  
41   12/1/19   $ 14,681,261.14     $ 109,850.70     $ 109,850.70     $ 0.00     $ 14,681,261.14  
42   1/1/20   $ 14,681,261.14     $ 113,512.39     $ 113,512.39     $ 0.00     $ 14,681,261.14  
43   2/1/20   $ 14,681,261.14     $ 113,512.39     $ 113,512.39     $ 0.00     $ 14,681,261.14  
44   3/1/20   $ 14,681,261.14     $ 106,189.01     $ 106,189.01     $ 0.00     $ 14,681,261.14  
45   4/1/20   $ 14,681,261.14     $ 113,512.39     $ 113,512.39     $ 0.00     $ 14,681,261.14  
46   5/1/20   $ 14,681,261.14     $ 109,850.70     $ 109,850.70     $ 0.00     $ 14,681,261.14  
47   6/1/20   $ 14,681,261.14     $ 113,512.39     $ 113,512.39     $ 0.00     $ 14,681,261.14  
48   7/1/20   $ 14,681,261.14     $ 109,850.70     $ 109,850.70     $ 0.00     $ 14,681,261.14  
49   8/1/20   $ 14,681,261.14     $ 113,512.39     $ 113,512.39     $ 0.00     $ 14,681,261.14  
50   9/1/20   $ 14,681,261.14     $ 113,512.39     $ 113,512.39     $ 0.00     $ 14,681,261.14  
51   10/1/20   $ 14,681,261.14     $ 1,109,850.70     $ 109,850.70     $ 1,000,000.00     $ 13,681,261.14  
52   11/1/20   $ 13,681,261.14     $ 4,105,780.60     $ 105,780.60     $ 4,000,000.00     $ 9,681,261.14  
53   12/1/20   $ 9,681,261.14     $ 5,072,438.83     $ 72,438.83     $ 5,000,000.00     $ 4,681,261.14  
54   1/1/21   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
55   2/1/21   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
56   3/1/21   $ 4,681,261.14     $ 32,691.82     $ 32,691.82     $ 0.00     $ 4,681,261.14  
57   4/1/21   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
58   5/1/21   $ 4,681,261.14     $ 35,026.95     $ 35,026.95     $ 0.00     $ 4,681,261.14  
59   6/1/21   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
60   7/1/21   $ 4,681,261.14     $ 35,026.95     $ 35,026.95     $ 0.00     $ 4,681,261.14  
61   8/1/21   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
62   9/1/21   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
63   10/1/21   $ 4,681,261.14     $ 35,026.95     $ 35,026.95     $ 0.00     $ 4,681,261.14  
64   11/1/21   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
65   12/1/21   $ 4,681,261.14     $ 35,026.95     $ 35,026.95     $ 0.00     $ 4,681,261.14  
66   1/1/22   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
67   2/1/22   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
68   3/1/22   $ 4,681,261.14     $ 32,691.82     $ 32,691.82     $ 0.00     $ 4,681,261.14  
69   4/1/22   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
70   5/1/22   $ 4,681,261.14     $ 35,026.95     $ 35,026.95     $ 0.00     $ 4,681,261.14  
71   6/1/22   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
72   7/1/22   $ 4,681,261.14     $ 35,026.95     $ 35,026.95     $ 0.00     $ 4,681,261.14  
73   8/1/22   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
74   9/1/22   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
75   10/1/22   $ 4,681,261.14     $ 35,026.95     $ 35,026.95     $ 0.00     $ 4,681,261.14  
76   11/1/22   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
77   12/1/22   $ 4,681,261.14     $ 35,026.95     $ 35,026.95     $ 0.00     $ 4,681,261.14  
78   1/1/23   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
79   2/1/23   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
80   3/1/23   $ 4,681,261.14     $ 32,691.82     $ 32,691.82     $ 0.00     $ 4,681,261.14  
81   4/1/23   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
82   5/1/23   $ 4,681,261.14     $ 35,026.95     $ 35,026.95     $ 0.00     $ 4,681,261.14  
83   6/1/23   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
84   7/1/23   $ 4,681,261.14     $ 35,026.95     $ 35,026.95     $ 0.00     $ 4,681,261.14  
85   8/1/23   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
86   9/1/23   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
87   10/1/23   $ 4,681,261.14     $ 35,026.95     $ 35,026.95     $ 0.00     $ 4,681,261.14  
88   11/1/23   $ 4,681,261.14     $ 36,194.52     $ 36,194.52     $ 0.00     $ 4,681,261.14  
89   12/1/23   $ 4,681,261.14     $ 35,026.95     $ 35,026.95     $ 0.00     $ 4,681,261.14  
90   1/1/24   $ 4,681,261.14     $ 972,446.74     $ 36,194.52     $ 936,252.23     $ 3,745,008.91  
91   2/1/24   $ 3,745,008.91     $ 965,207.84     $ 28,955.61     $ 936,252.23     $ 2,808,756.68  
92   3/1/24   $ 2,808,756.68     $ 956,567.86     $ 20,315.63     $ 936,252.23     $ 1,872,504.46  
93   4/1/24   $ 1,872,504.46     $ 950,730.03     $ 14,477.81     $ 936,252.23     $ 936,252.23  
94   5/1/24   $ 936,252.23     $ 943,257.62     $ 7,005.39     $ 936,252.23     $ 0.00  
Final   5/1/24     Final Payment     $ 1,304,809.27     $ 1,304,809.27     $ 0.00    
     

 

 

    

 

 

    

 

 

    
      Totals     $ 29,730,909.93     $ 9,730,909.93     $ 20,000,000.00    
     

 

 

    

 

 

    

 

 

    
EX-101.SCH 3 rgls-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rgls-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 rgls-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document and Entity Information
Dec. 31, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001505512
Document Type 8-K
Document Period End Date Dec. 31, 2021
Entity Registrant Name Regulus Therapeutics Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-35670
Entity Tax Identification Number 26-4738379
Entity Address, Address Line One 4224 Campus Point Court
Entity Address, Address Line Two Suite 210
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 202-6300
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol RGLS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 d277160d8k_htm.xml IDEA: XBRL DOCUMENT 0001505512 2021-12-31 2021-12-31 false 0001505512 8-K 2021-12-31 Regulus Therapeutics Inc. DE 001-35670 26-4738379 4224 Campus Point Court Suite 210 San Diego CA 92121 (858) 202-6300 false false false false Common Stock, par value $0.001 per share RGLS NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d277160d8k.htm d277160dex101.htm rgls-20211231.xsd rgls-20211231_lab.xml rgls-20211231_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d277160d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d277160d8k.htm" ] }, "labelLink": { "local": [ "rgls-20211231_lab.xml" ] }, "presentationLink": { "local": [ "rgls-20211231_pre.xml" ] }, "schema": { "local": [ "rgls-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rgls", "nsuri": "http://www.regulusrx.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d277160d8k.htm", "contextRef": "duration_2021-12-31_to_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d277160d8k.htm", "contextRef": "duration_2021-12-31_to_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.regulusrx.com//20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001193125-22-002665-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-002665-xbrl.zip M4$L#!!0 ( *")50[0^O0JA %MK . 9#(W-S$V,&0X:RYH=&WM M'6EOX[;R>X'^!\+M%@X0'Y*=RSD>4L>[=9M- MM%B_>EH"7:)E8655)*[/?K MWPPIR?)]Q$EVVQ38KB61P^'<,QQI+_XS&GKDD4G%A7^9LXKE'&&^(USN]R]S M4=@KG.;(?ZZ^_^YB$,) &.RKFLOX96X0AD&M5!IUI5=4S"GVQ6,)'I3LLETN ME*U"Q>5 M8% !1C')G63>R./^EZEI3Q4]R3H[.ROII\G0N9'I G:Y7"GAXRY5+!DN^YZ: M&BY9/_(B)4=%1PQQ"Y9E3S8P4GP1&@#:*OWY^;;M#-B0%KBO0NH[Z2)1*)>B M=%:"I\E KD35MDY6X!^/2">,EHVU8*P/NV5__MRZG0P/%X^?#"V%DOJJ)^20 MAB ]".FH4+8+]G$&2 %D8PI0(BOKX)QFA $7YZNV.D-%?.K.R&@\^+AD'L9# METL*RGM."SZC+OX=\M!C5Z>%WRY*YB?<&[*0$H108']'_/$R5Q=^R/RPT 'Q MS!''7%WF0C8*2QHB*>&\4@R4$'+1%>[XZL+ECT2%8X]=YERN H^.4058[HI< M\%$-AS,9_^:NRWSS&X;<&?DG/AWB7,9KUT/FN_ G_.C1?HS$*&RQ'CR.I*;Q M7RBM!DW? M9:/?V#B706G)@"U1*X/N')6/CBQ['K_2#&4DZS$)EHPIN$95KBFM<; 6T5:@ MAA;D,J?X,/!0\GWOW4 MCO6U$I$TEUJ!:C&Y-?*:N!)=!4 M^"NCKSBK0#W>]VL.[(7)W/3S)^Z&@]II\8C[YYFQ'NN%YT,J^]POX.\:H5$H MDCN2]P?Q+007),#0:!8&3#\%;QVD($(1U#*771&&8JCO=(4$U),[5C B2GC< M)3^4]7^YJY]^L([+YQ>E8-E"E?4+V3LOE %;!2!D?@.D!ZPI*/X_5K-.T^L> M'7)O7.OP(5/DCCV1EAA2_UP_>S)X=X7GGB]@S^]WS4[CAK0[UYU&>SDZY5=" MI]VH_]YJ=IJ--KF^NR&-/^N_7-]]:I#Z_>?/S7:[>7_W+!SM?>#XQW7[E^;= MI\[]W2&Y*=:+Q"X?5<]F\,HLNHED3@O$.HU:*)G'.TEFL0S#IH7SW&BI;7V8 MW_V&6CK93&(D%C',>BVI^GC?^DPN5$#]U! ->,@*<,=AX#R?) W F2R+(FZ$ M$V$0D8ED-O?4.DJ:=M$7)43EZEUB7D1B]J+C8(5:C;L.:34>[EN=M[1@;ZO ^JZR76\5KQ71W@>#12K)3]6RTA&H#"X,]2P MRN4/,>UJY1C-6CG)^1 Q:?YRIU/)2O4#5@%"=^;I(Y.@ M2+J6LVO'!D#,?> M DZ"\^(ILP#A?S'N,AD2T#XK="6C7[#JR5U6HX\")&1CPEF:==/KDHPTD2EQ MJFE!(C-[ 9D #+-!\:SVKC5:8&"$!!>IK5,[!+]5%Y$?RG%=N,_R@5@JQ9)& MR (I'G%9XP0]^@3^<&D\O:D8)#(_-_Y%:+ASWF&(_)%[#)Z!\]^A2F@5*D?' M)^6E%/LG$ZY#1\VXQN9H2NU(1?NX4#VIG%9.SC8@XTMH^^F>E'U7O[^7'#RO M[0-X_*TB$.L%,.%9JW5@O.C;*,#;,J0NAD.N\+3SS5F"-H[*_F!O-5ILT MAH$GQDR^.3^F[>8T9[2%@_]AI/C-1IX:Q>>%GD?E/8>,U=.O/61,].YM$\@U M;O_:=253*O[K%E(X:VN77[7M*JG380 I]8/@D)M"8"O#6?]_N+PLM P7>VM< MVA%$/L2V%@1QNUN)U^1$'7[>RXYX\K??.P2 -YSUQ:Z4UT''O7R +(+KKH@M M$:A?+Z+Z&WBH-(-]5L(64^5!0&[E_9<'N^1I5V>VM:CT^&W$P&OHEX\IA)6I M0(+(\(!ZA(V8$X7\$<-7<(I,'7S=F5,>6$N0MP=S;%G@N+LGD/13$%,0F^5ZCV;F&L;M)-/YTZ/3 M@_E6FITST%L!''O W>R:=);MPG&EO#QS?\X9REY8>%>Z?DXQ>3]1\T4WZ9 ]AUT@5>=<"<+_JHD :! M%&!HL330%2/299YX0K;A0V3N>AW4!^Q:*4B/>V@MN +3$3+?!;:' C@_C+R0 M^DQ$RAL3!:JG>F.]0CQ!=(%>)M6)CS SIQ(1P &1\L?)LQXD&^()YV%QDF," MK4A>,48^,9])\!=-'^9&^I267!?MHMG606VIP!WOG##M-2%*LZ!)9C2?@LVD M:)LY^EG?'6<\'U8XQCC+^G"^T $N,[Q_2!X"Z[&V$?EQ_JJ>78KN"N%U*; ] M!"%%G,].JM7S>=N\+AJ8K3.0:::39QONF::ZW%5,#R! EB DR/03M"*0HZI] M%$OZS D^'MSGK1-2_]@B=J5)7M?DMT&@^\ 3_S^9["68#*]?[%8 M3X@!H TUYF5ZK>NPJK2 #;G&>TS$?ZIK)1'^M=#L:KEH(!YDHK1W/7EE/7F0 M#*T_MG_KICV, ^1]K[=]$/X/TI>UP@M4*S@9LB5*L?3UZUE0J8O)=V]Y8VRJL4,T[^]6V&.;&VK;W?#$3CIK$C$E([8*E/;%H M&Y)L#;:[/._Z!DZJWGND7K%BO$&E9A*4KIJCXK2'A%8CV$@78N[B+5TL9BUW,F[Q; %0$R0\B.B_9)7XJG<(!1>X#G U01E_6X;]Y>,&75\A&9?RMJ\C)4A>11 M$$[.=6DU&P\!OO> IUH;AOYVMY#6LC9[$VL]T 0[3 /FX&?0++[L@63N MJK&8YD:+8EU:W?N00/BD =3-_%=+4E^6.LW>"KG$@_2%0L[GSKH&(,+,@UP* M1-@7.K.*%-.C@$;QB1I^HH3KLRWSW0"DB5[+&^/B3QR61G7P 3]X(MDC5S / M%(/Z#A9JJ>/@:P(X&#]6XE+I*G.6YJY,ZRIYFJ9U67$N9J4@Y<#^SG;_:5\< M, >\\3'O]]^!]UDHF6PX)YAX*Q,M=1FP'J(E[XF.%4:B !P_$Y-&5I#M"EG[ MX4S_=YYL*!A-E;U*,1*KC]#W^QF)[[^;*^S]?-^Z:;0*]?O;V^N'=J.6_/BZ M"WN6M;!L1_1/$*3Y>M1\=- ,V3!6L6+96A#)9(&]59%M5=QO=MG -X_PY%\0 M2I(S,G*#'IGKYJWKOF2ZW%8DV]2PCO=AH>=9H'_7> A;< !Y3[]R/"#I)XO0 M_MT*F 06,G'DX\D>R-I.H+W@?>^3Q>\>'Y*E[YR2/%IH;.RRR^?UQ%'#E75^ M0+0ZZP@)^>2CNS$;I]F-XZN?JS:?76&>=.EBVA?=C\!*N>2C]C\,(\]##-40 M@J[&A;IG Y0.7T&%Y2CQ=!5[:I%;?2L!?$CP)6V7_!KY+-:<$R2+=:Q!ZZTP M]W#*EYF,%$$:6+A*J*]C$I$?;%N)("@F!'!(/J9&/L>G@':1/ M@I"1Z"4AAKT/0?@]K20C.BKUPW/$/\SN*>WND_A5,.2[?K/=&X,;&>-HA:3) M$ 5R3+S393JBD#IR@*6XEAH%D:OO8>N.%%%_H+DU:1+,\P-#O$1@B1%5^S") M=/""- 1D*6&?L,_GXG939,.<05L'(,?X8#88023YTL@5Y8#UI-5$94C$:&Y M03'SR)!!1!6'8@[C8"V[XRP10=I _F&'6F0I2B(^>17ZD=43F%F6R\"X=1?2%SAYY$'@6Z+-;$- .YQ)#[%]97/G\[%O.XCZF92+][I:Q=VAL8XE2KYZ\S2&= MN\J[!RD^*Z39?NGN@OU(^P;M!5B@B5L,XA^N84%RM4DS0&55,\!9=:H98++@ MBY[2S!9>'Y#B?G@KFN?G, \EXVLLE4G\^74>7HTN/3#(7G"9R\Z8)/%M B\Q@=.MJLRYS] MRJ]!;RP$U1>5@;J N^0!=@BI%08VC@X!;VA(B?Y 0MZ4+' 4TH'@%\-)2/M* M9\W(:AC&'ZH[R"I9:CSQYZ0JK'7OWUL:?M/7V]O-3W?7 MG=];C?8N\:$&R'W\?D.M^F'+>#'[E4E3CM 1>)IS;'"D>+CH2,F-('EQ:(3% MG$P@&!=Z%.P>JSPF$NVR ?5Z21RJ^Q?C 9B#11B$:W# K(&0L#%W53SY[7K@ MA3YWIJGW*'&9VWCAU=^@V KBJMZ^_:-V]*H!0NJ-*BN#Y>4;_4V#<* !*.X9=<:]/UHR-34=Y#F\_F"O5,R%I,?Q[7 M7@[G[7K]UAQ4;^FR2JI$?A6*!0/R4"2_T#[U7[W5[]58^2U#GF/2.X.^+L@/ MDBG];Y+H)+ ^X*P'$5Y2B+[7'SZ1F^8.%R7S;_GH?^GGZO]02P,$% @ M H(E5+D0(P_2+0 -1\$ !$ !D,CU=;7/:2+;^ M[BK_AR[/YE:F;D?1^XOCN K;..:6;5R83';VUOT@@VQK%Q"+8!SOK[^G6Q(( MC!W B-:!3F4F((3TJ/NG!,]O=@I].@-PP&QT=G MM3_(;?//R^K7@Z>P/7P\=!4K[!T0OQ,^]+X>=(+[X0$_UDVV6]?#9M@-8G(=/)%&U/7A M3)7+VK?KKP>#\.$13G5TA4/"+HL#C[[TPZI';X2 (AI3T_+[?@K/2R775?]Y'@_;D>K[L[[&K2;^;?8$UU6G4Z0"F M 1RG\@ -D3O([$>YYJ&$->,E-%XPB.&Z8W95["I:CT%[U F(!KD!O<#WBJ ! M*@]P>;RA/\))V\%]V(-OW 6=Z.EW0F"J$9 M3J/18-S=N@;=?0O-=!8&#Q$EIQ7BZ9JND8]CB"?18! ]Y2_J=X5L/)E_0$M4 M*[=T3MAD 'G+99'1]P?06=#6@P"Z]F4_/_J0L)S6 M;';/,C-% M.NQXMT%K-&#]/HXCNK_73EJ7I_O_C'I!DNJ:PU)=LWF@^2R_@S8E\:C?[_ O MLD =D(AA>@KC@'2C=G@?PM87Z&:#9"J.IY*A/QK$(Q]Z%;[Y]!A"-&8-P"^P M/X@@5>$4\/&XF;)K[,!A63H3OP61U/9[P!,\C-C)H6&Z<1J]D/ LQN+]/=Z> MT7T2UBP&Y@]_!8= =B5T?+$,SFQ@0*['X8"W*>^,\77S1HG9!;U"%-!]XX9C M%QSV$A*+1W?_A#SFO?1*$Y$X&,)5#* 5DV\J&V^FZ_H/RHFC"D-'E;(.!GPQ M7$U*%>E%PR5V(0QC"A__%?0@B)*+\;-V@/Z&+[(F&[<#Y7OP$"8/4=3F;__R M.R/_KA-,GR:)X0$,AF%_F!RX'?Q[Y+>>&8 D5AF)L0.S(:_UKU[TU G:#RQI M%NSA[+L,,>NU>]@A>HH/7]#3I %M:+\9H?:B PZ.DX3F/_%FK\QVX0%)#O/U0#T@I]7+RYO*V5GM^MOX_>U-Y31[ M_Z-VUKSX>J"IZH>#!$^#Q,-G:/"OY*#O/P2?[@:!_R\(&-;ZA_Y?4=A.=SS+ MOFQ^F%Q4\VSF0^O# 0SSB=2#1AG+OD3C:DK^*_F/IKZ4CW$RW<+DO4+T"YG! M=.KWPR$H\?\P:N-I.(K'04KN1D/2BX8YJLV&_?C1[W02:DRB,^ZGVJT;^#T8 M]6/R .]Z:8IW6?+ O_M[,PS!(H.W"OROP?['(B3? C+@5@\XO80!=\O").JE M [WQJL:$24%&2HD (-E+)BD9B4',#8$@X1W[>L)8[!T/T:EQEHW,,YSV9LSE MVL!^96!)-[%K.O26'5C&>@0: P8\4NG".!?^)QE4IF=U1%^8)\2,Y\3M,"DZ# M/6<<>15V.KROV3@,8_+'OUE4A?DB_*>HZIQ9@63!U5G0V H6O(>Y)A.+>39L MM]]B/Y)Q'U?=G?ZC?Q<,PQ9H/IBC!(,2\.#129HY+^@FR1>6.:P)\OH7KGNB M:=M "6D+P'5!P_@#\AS _]@!*;3I_MZHQ\:)0=ABL\8>S"E:+#5!LK>"H,WG M+3!9[01^/"3-)SCS\YSDU-5\=J:S3#AG#.?DK!K&;.X(LSXX'*MQ!,FEQ,F4 M-PQ>\J9,Z-43VBQA0CQ)OC&9(R?I_B8$V/_H^[CT73GZ_/V8I%6= M2>5UU$^/Q,?[09 &-=MR [G6"OO 'S?^4+R[R*VD#/(+^O )TG!;#3H M1W'PLL;'!].DM' W69/IP]@?QD$'YC7 84\PH@Z#_*YLAG/'2A- JYQI/_KI M' >V^KR8%B2%7;:>,T9+R9,/J :LEIQ4D%OCF&8[)L4Y5A1A>XPKD]G'7*F= M1:U1-=>MI)N02@_W/49NM&["M\ 9*"E &H%X$EI/968 M;Z3OY[/:'_ ^7='=WR/\[U$_B?[I4FS0?1%D;%,N/>X"Z'-(C\Z3_QRSI=^C MBP:YK?T#XM4XR [)5Y0/?_/XG^G4RR+PM'K=K#9676[>>3JY*R6=@-R9K.B. MJ8#E\' PXBM,K./EE6Z;J&2%F M2[+YO,JM]&:!F"5!$NAI"K"C[.^]>9JEZJH['XI;)OYJ76"K$&*C [+JG@7; M0_@7*\@D[$1>!-Y$F24EG2GFS4<>D"^9+)E.K1WE6)VM2<.@0-FZ^VC )LL) MCW;[G6#(Y1'CT"X+WM#O9(M4<6ZNS>;>)%F*)Q]3RDZGZL'/(1^"1B#+?H%T M$+ $200F"?Q!)TRG]7S-.%%V+3_F2V7/8]@I6)ADMX8I)'XR]L7?:3+9'TO* M7I35X9DOZMX?=8:@ >-LFMY.RU"\T<+>"#KAB\S'75-/$U;WDZ)I?^SF:;-X M&PT?([Z&P@:'GT%KE&9,.^CPB=!,LK*/8,]^, #=T>6%S@N#OX]2AQ,_,",K'E !I-SIG3_T@V7:N^W1ACV MAL_$DQ)$T'O=K38IV[*)Q" [$&=K/G31,NZ0YDW TF^?F M6/HYOP26Z)B7K,VX/Z%MOBPU\XTU,3F%+.:1S^50F%;B6$P/("=ZP<2XP,I/ M'?\IR8.'42=V%B9F#U=1@E$K2&MY/UO$HT7)\46]2!" W M,!^9/NK4@?)'X@N@='_OGZ/V V^TB'%/BYG?TNI>BWE[QRY3\A!!R_?8KGSY ME/1'T'PM8[< MAQU('38B,WLUSR).)"%PP,2TSW>%1NKV$W9YY@B6R=S]O<53=U+?\SL0C>UG M+KJY!HCNTGDKK]6W ZEX"\W7^U+FZU06CD.C/>H\9U.O=CZ/DXR:N@$C-;Z, MHV^R5I0;#& 0"WI<+R:+_0\0>?%P38J#L93V,X M9LR.8IY0 C>#N$ M<\7,/V1_21;J0$Q%/C\E=]B,08O8@BJ^)Y- M$5FXL"5*5A-IAW'K$8 %\=3]SOI7-&V"6$@'Q(UX!@FA@]!^PLR0UE M WC5#EG!+V(O^Q"N02N(8_[.A\L>](+GR7(5SQ5XFP0W'[S8?6J)YSEBV]F8 M=!<\^IU[ED4L%X9)79.?)'>/RIMW?TQN46LDS1+$4_=&<4V!.;"8=,' 1W0][:H*QYXXR7UNA8V&"6"GO&<738;^OX)>(EY T4QF1$!YT;@^D:M4TXD#(*FZ MSU:RLU& ;1_W*&4A31.#%QR6)X,?3_P,79^YT=(.)-RIP:!,VI!9SSI^%GPL MUM++CT;#5^RKJ=\CX?R9ZOW;UPCO!]'HX7%VNT)^0+.R,_)A*7-_IN,'&[52 M)"Q_'R(N&Z?*/=SSD:;8/5MO]9/;29-02^SR++ AX)HPY^9@Q:5$V+:# M>R9?68A.CI+;RJ,\&"1!F07GW.P(AL -\61H3,:L9*F@'=%T(3AO^YB[?$%S M-]SRQ97T,!&S;\P=^=@M]_U7;KE_0<4DS\7NS/!7^)W[V6WS.DF'6^E)*;&. MT(RY0N)U59#<'AG$P\.9!4(6PRS6YRY!\UO&T_O'DP6- ;.)<7V;1G]RFQ!; MI S8'>MQ:Q#>C=<39PCIR\2_Q1)\?&_KG$EU-)D=[^_E#L#*.:WI@E5[U!K. MCL'C5!]S,]D@LS+/B"P=%>,7<4HH@ZOC.5[PDZUBQYWG%[Y+.B_$DH%GO$3Q MVN($USD0J.P>D^'XSNC!Q&>ID.;\FM1,V(X7V9/E=S@M*R)-[B6_8]G ,S&[ M?3R1+(E=:M2'U (YG<9]#P;_89@NUS,T8R$I/5/%YH!;PAR8U%42D<=6M4&S M]X>0"WV051_9C?]V!5&&/LN@1BYR,@([9^S-0![QFVH-6:R6\ M^CN?JXUZ?3]L[^^E))\6(*H_^UP0,G&6^#1>T;797"2MN#RUDC=D%!K?7@GC^S7;;&J)GWVP4G*G4/ZQ29/[?IA1 MY)65AKEFP)?J"&:67)HE#XY)[S :KT/XS]E.^34(OS<9+\A]$,Q=_T]EF]]E M8K]P(8;J)1S$Z8NX//TZ9OKI7\7]A3+M3R)TC* MLN-"/+_SY)GT1NQQ8RRRTND["V%6QV/A/'[6RFQVL6>#P7PC[+%E+>[:XQ/V M='>:EG>&T4/ Q#J=Z*IX& Z9!2OJ!>/\B'W^Z"QF=G_KEBK)Y>N)U3(^DN45 MM9R;TN96:\?/($KKEBG=CF,T6?Y,[Q=/'$?C&RD@4.<\KRI;DF&O;[-"Y:G? M"4'X]T)_@8C 6>J7_;W;\*'G\SNFV/Y<#)YS"_O1Y]IQ>MS_&S]H$6.9S-CR,ME2#?FN M1X!!*-2NX0J:U]7;6\*?FU8_9Z%!YV4=K\[R$F\[$475#I]./.;2&79+ZD;S MGXF7.@$G2\33M=[[\VRAL48M%:C_J/:.$Q8)X,T#2=WW-QA+ZJU;Q=-N$A[YJBO'&5#%_7J ML^=@7U:OS[:) MS%\^.UNR>/$L'G78\X'(A4+. Y^5#CK/2-F\'%>R#E:_#7IL=>D/5ON_&00, M('N.]!Q.EU.O=T_RV=.J_GY1.ZDUDXZI$/;,JE_\ L)K#ZI[/Y8YS]82B*=V M?,/- S 9G#SCB\T$:WE$,@3?U\SI3QUKKW_Y]16EL[8P4'W^ 2Q3F/9> MN@J??SBIIJB5,^^7U854FNR_:[K\ \H%YCH1&'SA\\>&;+Y\71' X!-L_C3I8L*@[\M M3QR60UW54_02$(BE6.H'&6/OBS%CT,ZMQI\'A2CXY>-,MU)_(C;QOM/!=![> M3YD[9#C)<'I/62'\6>5,IYL2Y4!A2^@ MTM\_K-5)E3U1@]]N#3%5BI#2)$=A#*D*OSNL1#6DJ1^/*TLH34KAUK*U-ZDVC>EN];K+*^OEE'3Z^_L8+Y["Y21J59I7 UFME9MOI1:7QK7I& MKBI_DK/:^7FU0X<3-BRJ!XUS=DOHY?\,.3BK? M&M7J%:#8]4H\7T *NV2\D,3N82Y1?GBRO"HH$LHAW4R3NIZIZ(LL+**.@Z+5 MP1:JBNUILGW1;G_A5JG%7$?&8O8H>;#U6_ MM5I!<']_4 I95\!T,Y,FSF?M\UH]LF]U^;2/(X.P1*AHQFL'>3FO'P6_AO*. M<%[?XO3J%;'-3C\TH8'J%AFH9>C,S8/5+)/:AJ4XZRPVX$%:(-["B]ME"-@\ M^X@8-W6A?.1)/D*1Y7B02C["I(8,H>RCJ9)^UI[4ID=MTU&LW40JZ0>W'#+% M$I(F"0F%RL"#5!(2)CUDB:4?7=(/"I6!!ZFD']QZR!9+2(R/UGF7;-FZ=TM$ M!AZDDH\PR2%'*/OHDGU0Y#0>I))]<*LA5R@?&9*/UI[E!LQY'&U7D4H^PJ2& M/*'L8TKV0:$Q\""5[(-;#6FJ4$*R)"&A* 'C02H)"9,$FNF]B0AH4AS M/$@E(:'20X+-U*KD'Q2S'#Q()?\@%T2"W=323HU#9^!!*AD)E2(2ZZ?6I*$: MA\[ @U3R#W)%)-91S0616_;,P45(4A!)0D(CB,1:JG5)/RB2&@]223^X]9 N MUE)M2$):>YK+.\PD(6'10[I82[4IZ0>%RL"#5-(/M1S;:I;=N*O:1)9L.J2*RQVD5!0N_H31&I[5+-TQ7+VTFD4A6M MCWZ$J"*QOFI/$A**-,>#5!(2*CTDV%:M2OY9?U8;U-1T14/ /P4@E?R#7! ) MME7C\%7C8B2JJ3:U=$OQ$%2*<&DBSW)Q58I,AV@3-=52G_G7R:85/=U!1KG2%0:-M:EDI-PU5L+!H)0L%RJ.N9BF.NSD0B M-)(AUFK-)5+Y9Q>K]Z\(:E(MD^I HU[IE_TTW:6.9RD&DD3W= L7,5G4,71J M6K:BO8.8-D!#8BW7.@X:6KTW1:0V:"13551M)Y'*VM'ZZ$>(+A)KN38D(:T= MK.I1UW85H_S-6@1224BH])!8R[4IZ6?=8"U;I89A23VT=KPP(:,V3"(1D9#N M&=2Q-7RJ2*SQVL)"2ZOV[^;!.KI-/<-0;+OL2#7-I.:ZD1:(U]9T:JW;?%_H MNY)^4*@,/$@E_2#70V)]UYXD)!1IC@>I M)"14>DBPW5J5_(-BEH,'J>0?W(+(%&RR1N*R1L5(4A%)1L*BB$RQ[FH-B;T: M%?](123Y![$B$FNO9H)(+W_FH"(D*8@D(:$11&+MU;JD'Q1)C0>II!_D>DBL ML=J0A+3^:8]--=?#<+]'$4@E(:'20V(MU::D'Q0J P]223_(]9!82[4E"0E% M&1@/4DE(J/206$NU+>D'AU)PD)19KC02H)"9,>L@0;JE7)/VL'2^6,K+BV+>27 MR(M$;."51H*MU4B\U:MW\.;!FL!-%G5<=;T_/%$0-Q6 M-"VQ<9-'A:1)-9D MK>%P6:_>FYO':E'5T?D/X+BE_X6V(H 6V[3(: AQ\4BLV9H+I-*[@C'-W0R; M:IZI3"O?70$J*T=K(Z,-4(]8H[4NJ0=!1J,!*JD'MPX2:[(V)!FM.\=U:GN: MXI:?C H *LD(DPX2:[ V)?4@D!=H@$KJP:V#Q)JK+4E&Z\YQBZJZK7C6+@*5 M9(1)!XDU5MN2>A#("S1 )?6@UD&V6%.U(\D(@;Q U22$2(=9(LU5+N2>A#( M"S1 )?7@UD%B'=2>)",$.8X&J"0C3#I(L&=:E=R#8&J#!JCD'MQ"2+!16CJE M,0@,-$ E&V%20F*=TIJT2F,0&&B 2N[!K83$6J6Y$"K]F(V*C*00DF2$0PB) MM4KKDGH09#0:H))Z<.L@L59I0Y+1NG-L5=J6U(- 7J !*JD'MPX2:Y5V)!DAD!=H M@$HRPJ2#Q%JE74D]".0%&J"2>G#K(+%.:4^2$8(<1P-4DA$F'238**U*[D$P MM4$#5'(/;B$DV"@MG=(8! 8:H)*-,"DAL4YI35JE,0@,-$ E]^!60F*MTEP( ME?Y7^E"1D:91R]8Q>*5Q*2'=L:AANXJ!AI-,U:*N!Z%0;CTDUC&M(V&@53M3 M0%ZK'C4-0W%*WZJ&257;4DPDO[Z*CX$T0Z66#AR/3!6Y8HW3!A).6K5[17"2 M277-5-32MZKN4M>T%$>JHF("@;J6137+5I9-L,VJ(E>L?]I$P4"K=Z8(!@*D MCJ58I:\2Z1YU54?1D52)\#&0Y7C4<1W%>P<#"5%%8FW4%A).6K5[17"2#NQI M*';I:T6Z#4UJ*894104%+1/(IN8I=KE5D5@WM8V$@5;M3!$,I%)/J0: MU3U5<=<)5#)0+FA-QZ6&9BZ]'B!<%8EU6'M(.&G5[A7!22:U#%712O]K YI' M-5M;KWR3G)0+6EW5J6?:BEEN52389ZTBH:!5>U,$!6G4A2FD5?IBD693$Y2F M+HM%Q30O]72'6HZK:-ADD6"[-0Z_]>K]*X*45*H[&H+5/LVDGKKFQ3Y)2KF@ MM2TVFGJ*NZ1$WK N$NNWUG 8KE?O30$4Y#K4@:G9]%W-942JZ9#2NF)*:U%! M06LX-G5-D,COH" 1NL@3:[CFLJCT)N;5NU<$)]E4U0S%*;W=45.I;5J2DPH+ M6DW5J.G ;+C4LL@3:[C6D3#0JITI@H$,ZKJF8I=>%;G4TFS%6"=.24"3UM5M MB%I3\;!)(K%N:P,%(:W:N2+H".2;:2AFZ=?T+>HYUGJ]!Y*.)JUKJ3!9MQ5[ M2;P;5D-BC=8F"O)9M2L%D(_C45NW%=,M.U*3ZI:K:.O$*=AS^_L'/,LBS7M M3-Y8Y,9_[@+VLN>UQN^1&4'#GT?WXA+]AA MD6,7C!K96)Z#80Z!>(.IT0[(OV_:%W$6#=C#@^V@03?V? M)(XZP.J_J?S/Y)0W;P+;S&E7X@?90JOENFRG#7.BB D?!HI;KWQJ1D._$Y== MB^@>M30')AF>HI5^9;\@K$4VKTJ!&]A_4D&5)]'+<58Y[LD6D@H*EX*"SS\W M*R>75;[KY[/:'[#]E-=VX#/"_Q[U23Q\[@1?#W*-H@7=%VW"-N4DUUUP'PU M_.?X@)WJ MBW]@]H7N,@.R17;H>_>?S/ ?E1.VM>?#W05/7#>.@YK5XW MJPU.T'",%-P10,TZZREL#Q\/7<4*>P?$[X0/O:\'G>!^R,Z9Z]/I+IW;H]/* M[TV9^*(2=G1R7/\)5]PFK-#4:P7D\O*4''T^.68! ,@W"*32C0;#\#_^,(QZ MI.G?=0)!0!K!PZ@SB@D7CV,,N4[)'5^'X\\@>@$HGU,\N%GLDM/JY>7M3>6T M=OWMZX%ZP-_?5,[.LO=34752;YQ5&WQ[BB'9\@E"\;)R7/,^DQ18]@#[_ );Y89IN MLC;9P!1M63I/-S'FX'S.Z&P8_!P"L#;TZ>&G;.,R.<&2X';H#X;DS!\&AUD& MK(/]?[G'C':W/^OZ9UW5BK7Q+3E+_L4!2M.'1[7CH^_'9V'CFRO59I7%&*E?U1K/VCTJS5K\FMZ<7U;/OEU6%U)ILO^LZ M_ -BZ?JL>D::=7)2)=]OX>5YO4%N*G_6S\_)S??&3?VV>JLDO;2[,=L,!EVA MH6H6NU8V%53?_T[^T5I1KTUJ=5+].0S@*J,>BQ]1U".Y M!U?X5+K12'!]9O/&J,6KS]:RU6=K4GV>6V\FC>I-HWI;O6ZRVO3Y91T^OO[& M2\^PN4D:E6:5P-9K96;;Z46E\:UZ1JXJ?Y*SVOEYM4'.&_6KY,,;>,?/.3[- M2855K^'$S8LJ@>-^U//'([ZEM:S )DSO,J MK?2EUU[+@RU_L")2WIV3\1G&A/6/5_5=N@LMR%XUE[1\KB8_$" VV:G=FE_OHZ\BO71R>- M8V8_&^ODE=$ Q213!/V=R$X"Z)I>V'M@V$[\#C/,OAO>)B_@"D+@L?/,,=\- M\HV-Z2HRX8@*],T@[+7"/GOR 2+4U5Z;A?LD7I:/^J,9#RVZ&Q^S.<&,Y& _ M$:HM^7MQ(W.Q]:\@&^B\6: MNT+NE*'I-P]6LTQJ&Q:&)WZC08JAW]?$#R(&VR6?L+L88WB2,;8N#_$@Q=#O M:!3%D@_!78P?^ ]#2H)8*.U,C]JFL]X?N-]QI!CZ';&D6/)!M0M2AB8I8^M& M:CQ(,?0[&DUA%4(0NB2(K1NI\2#%T.^(-<7[2O>O409C# =?9\B!>AN08NAW M-))BR2Q>C!]TR0];EW5XD&+H=\2*PBV",0S)&(OFH0'*WM$D4LD8Y5047A'\ M8$I^V+IQ&@]2#/V.6%%H:A&484G*V+IB(1ZD&/H=C:30"K%GVI(@MFZDQH,4 M0[]CUA2%^#,=21E;-U+C08JAW_%HBD(,FJXDB*T;J?$@Q=#OF#5%(09-3U+& MUB4B'J08^AV/IBC&H*E*AM@Z+8\'*89^QRPJBG%H2HOF]HW5>)!BZ'<\JJ(0 MCZ8F39K;-U;C08JAWS&KBD)J2(+8N M[? @Q=#OB#6%7HA-TY"4L6@BHKF? @]2#/V.1E/HA=@T34D06S=2XT&*H=\Q M:XI";)J6I(RM*QCB08JAW_%HBD)LFK8DB*T;J?$@Q=#OF#5%(39-1U+&@F ] M5Z>>JRJN47:D>#2%:QC4, S%*'^;>E2S;6K;MF([JQ/'!FBB$+.F*Y(FWM'V M(I+/I9JG*]8Z?Y!VQY%B&![61!!"E$4A7DU/4L;6)2(>I#M$&1L@B&*LFJID MB(7SSJ"FIBM:Z?,.#](=8@@AHJ(8JZ90KR8NSJ"::E-+MQ2O_+-K-+K"LUPL M%0N7ZNIJ8#>L+@KQ;&I"39OO:'P13&&[P&JNJFCE9S7#IKJI*99;>J34LE1J M&JYBEU]G0/=;#G4]4W',U;E"A,XP"K%OMN+2#[0&2;,NC6) M=*=J&.LA""':HA ;IR$I8U&PJD==VU6,TI<%\"#=(]B.0SJ*7I"&0] M'J0[1!!"E$4A9DY'4L8RE0!+59SR!SD:I#M$&1L@B$+,G*XDB*T;J?$@W2&" M$*(I"O%R>I(RMBX1\2#=(I#O$&1M@B$(>$EZ$W MY%"]#4AWB#(V0!"%6#9U21!;EW9XD.X000C1%(68-0U)&0N+>YMJKH? .XT' MZ0Y1Q@8(HA";IBD)8NM&:CQ(=X@@A&B*0FR:EJ2,K2L8XD&Z0Y2Q 8(HQ*9I M2X+8NI$:#](=(@@AFJ(0FZ8C*6/K1FH\2'>(,C9 $(78-%U)$%LW4N-!ND,$ M(4)36(6X-#U)&5N7B'B0[A!E;( @BC%IJI(A%@5+\:AY1$@1_3(E$"]:>5&, M75.L7W/U[M@\6!/8PZ*.JV)XU#0:I"8B]O"P"(U"C)N:4.?FZFV_>:P651V= M/Y2^_+^ C :HA8@H$!:R&337/5*:UG@2ZY14,- 6, M0LR;NB2'+Z)(''(1HB4+LEX:DBP6S$,L=$FB [@Y=;( <"K%?FI(.I(LM&Z+1 -T=NM@ .11BOW0E.6S9$(T&Z.Z0@Q M48C[TI-TL659B ;H M[M#%!LBA&/.E*MEARP0\&J"[PPY"Q$0QYDOIOMRV01H-T-WABPVP0R'N2TW: M+[=MD$8#='?808B:*,1^R<7$DC72$G2&'*/Q ]T=NM@ .11BO]0E.6Q9SJ$! MNCOD($)+N(78+PU)%PMF(98[)- W1VZV Y%&*_-"4Y;-D0C0;H[I"#$"U1 MB/W2DG2Q9=5!-$!WARXV0 Z%V"]M20Y;-D2C ;H[Y"!$2Q1BOW0D76S9$(T& MZ.[0Q0;(H1#[I2O)8<(W:6>92EV^9L4#4?HU%5= MZEBV,OV;%PB412%F3$,D:ZS>&0)"W+*I90-KV&5'JJO4T( U2I^+>%A#HRX( M2TLU%7/)[M^PLBC$DVF*Y(C5FUX$1ZC4,6""7?Z -JGI )E)92$Y.\BQWX? MZH*O>>6SDJ.;K)%(UQ\\A+U/0&:'0') B>F&9%^V[0NYBP;M8,#WT2 >^C]) M''6 /W]3^9_)*6_>!+:9TZXE%F4+R18J#9^)F/!LDA37*UN:T=#OQ&4?5W6/ M%4&H!R+ *[T(QX155V$.QO^3RD4JE]T;=60+R182SV?P^>=FY>2RRG?]?%;[ M [:?\M(&?,:WG=3/_H2-%\VKR^/_!U!+ P04 " "@B54@^X#^DL# !\ M"P $0 ')G;',M,C R,3$R,S$N>'-DO5;;;N,V$'U?8/]AJJ<6J$1)Z::( M$&>1-AL@0#8MO-FB;PM:&CM$*5(EJ<3^^PXIR9:=V,VEJ '!%&?.S.'9IG MZ7&>)?D89I![>U!QAP5D[)B17@Y9<907Z4]P_AD^!2,*;D6-8Z1N5D8L[AQ\ M7_X 72AE4(I<0670G%5"B[ART#X1[A290+G4L+4PRRQM&CNL4IZJTM;%;:\ MPYJ_?P= X5*V4&2RK2>1CT,?AN7,R$2;!:N<86[5(".EF+30B#(:0?\=]PA# M>? 2NP;.N9T%T"#QX4GC-(N/LA'.+*3=CH.,((H7ZZP#"BV=4)V,GCR /1P&0G9R< ML"#=H52Y[7/TUC^P3ABT_<.=,V+6.KS4IK[ .6\E(5OU=\NEF NL@B85;HW* M;>EL:SAN%NAN>(VVX26^+.I48D\=COAF[,_/UU]"]45G'@ 0"E+4C38.NKJ\ MUF7HE@,Q]6_QD(K8;\593HE,R%@$ZDG:>_(([,U$A@R_BLBZ/)Y-Q.XK9K^( M-U6]C\.A1GAU-';;W:ZWZ)-7^+% M4.=3G$.8< 4WI=$2#\]!UAC=H'&"+H5-JW0&[@S.)Y&_%>)A"GV3?);0%!I4 M'CG8;CXO9@1!>;VA-V"=SRUI@%]\G5X=N#[6]P=S?*F5KE<=RPM=MOZ.&O[/ M5?5)$;?5%966J0.O" 1=-%-2__8L]37+@6>%]+$G0OUFJ?_1M^!@8;SDJH+. M'(SLG;)=([OV6XO5;^HLK$LNRU:NH]Z#>XU#P-U\/1^Y8;8?U^\.&1OZF.TV M&ULS9S;;MM&$(;O ^0=INI-"X0ZT$6 "'$"5[8+ MHS[!5MJB11%0Y%I:E-P5EI0EO7UW>8@I:TDMS=G0%TD8EOZ#5)^>/G M313"(Q$QY>RX-^H/>T"8SP/*YL>]5>QXL4]I#^+$8X$7UL2]SY_>OOF MXP^. Z?G%]?@P"))EO%X,%BOU_W@@;*8AZM$2L9]GT<#<)PB?C+] G]DY<9P M1T+BQ00B+TZ(@%]7- S&[M =#=^[H[Y;3A/$4WH0> D9PVCP?B#C7!B-C]SQ M\!,C9[*>NC-&'TX<.'07JT'!U37:P4'PW^NKJ\]Q08,&H3)"_<\IPARURQFYSM&HOXF#WB=5,#\[WHR$ MEW(+4@]CP4-24U@=3JOW\OADNY3Q9),0%I!<^9LV]_.HA2 /F:I"+Y6,B=^? M\\=!0*@"9*@V'+7A#$=YGS_*75\G7#)_,HL3X?G);M50G2@NBIVIE>.>)FFP MVY:*.Q'^CI8G_$)';AXX"WG$P.?RJ[=,G%2Q2'\0/-)VD9?CFH-?PUFH;5/Q M)+?4B!/F?+D_Y#43*AL3).8K(2%K\@5._7Q*E>&?0OO?CX.GVJ^E57DAB>G-3,)\E=02FOG6N.=@&3(T0$IC?E$%)M\;20J-E+$V[ MQ8#RC"4TV4YD,>&%%_*2O/F=;$WAK$CN"-)Z*[PFJ VT-8)(\&85("\!:0V0 M15IC;+'U,L[-^\< ^Y3[*S5#4^G!E.?=G(XPUC;.]X^U@79?!XG50AB4.IM\)K@C" U0ABDYN5 %D#5!$T MB"VTKJ79N'^\Y<,=F5.UA&;)M1<9T7SKH]'!7#D\50)5 M6C?8Z%NS;#!N'@_G"^9SL>0BO:ERG\@AFO"57+QL)SQH2/K:$9$L[DIYW4Z)!H# M7'^\/?[/M7!95^J0R2-AC=VOAF&CIO%PG7J;BT NHN@#S6ZIOX3=2I%.03YD MC1L$MT>\5AB7=UD*=FOATF_5BF847N ';S!.@D#:B/-_+BDCHV9#H17H="#J M+/$#@>T'H5(4=PAR_7?%!JA*<,.P5C;6;&@&X 5>; Z VW8 W%Q5&> "5"% T#H3>E&X>= M2+1AT*A:&H6L$LA2F'JM0EWC?/]8JW<* M]W20\$V_\RME'%KQ^]QYG]"P60PV"LX;WU_?S.L*RT@#7'V^#IUX+ M"=%4'%)UK#N,=OHMH]JD:0Q<_Q0T20B;\"A:L?S^96S*;$5R1^#66^$U06T0 MKA%$XCBO +LE6K-LL?$RT$V[QX#ZGH?4IPEE\RNY'A?4"TV)UF5VA'.-"5X5 MT0;D*C4DBI_DH=!OC;"MELO\-NH; ]Y;0=2L$ E'^HZE^CR.N'EX,%]*U"ET M!+.!*7XHL@WQ?Z,3" %S$\8J(]F.@T7D= MPU!M4#\2>_&(@U&A;6L\LG)6I\22H]I9:60+9<%#_)5<9VU'[FQ*D]#X/LA^ M7E>+G2H#7'^\U4)'JX6US,G%0:I#*M]^E6.EWYTU3H.F,7"="D]]VOU^&\VX M\=+\65)'H.I;YYJ#;1#5""'QF2M#)MV:30N-EL$T[1;S&GJV\1?2,VGRD0E] M;L?74JT17AV#<4W=U\.^KA85<#XR8:]O[?75L'F\9X-G$1%S.4&_";Y.%G*1 MLO18PX\15TAT^G2PWA8_&-K^^6"-+!+Q^4.UHA!DE2 OA?1\T*(-S0-"4R_E M'9=R2_T*F'P7S7X1BMSS/U!+ P04 " "@B54_0FR"L8$ #0+ %0 M ')G;',M,C R,3$R,S%?<')E+GAM;-V:[V_B-AC'WY]T_X.7>[-)"R&AUZVH M],1H.Z'UEX#;IKTYF>0!K#EV9#L%_OO9(=X(A![T=E.\O@#J^/OXZ^?C.+&3 MRP^KE*)G$))PUO/"5MM#P&*>$#;O>;GTL8P)\9!4F"68<@8];PW2^W#U]LWE M-[Z/KF^'#\A'"Z4RV0V"Y7+92F:$24YSI4/*5LS3 /F^K3^8?$2_;IKKHA%0 MP!)0BJ4"@7[*"4VZ43L*V^=1V(JV90*PB8<2K*"+PN \T/4B%'8[4;=]AOKW MZ*8(PM"$I+"MY-E:D/E"H6_C[U ANN:, :6P1K>$81833-'8&OX>#5G<0GU* MT99)2Y6$T%;7$QUV[; MG<"*O&W-:D^T[!22\.+B(BB.5NM+4E=;-Q &O]_?C>,%I-C7"#2R>*+H.C"BXYG&> E/VN\^2 M&Z:(6@_9C(NTZ(J'BJQV%P)F/4_,J?1M-&/HW4@'^G1*(+7.]'DA29I1\%"P MU:%,Z,'#5%'[3A=4!+!2P!)(;!C3@:_5Y:L-UW+P\KB2 GOV%M DQ*TY?PX2 M(*;%MOEA\M/VVV&)[)TN^C3@>MKH3Z42.%;53% S9KBPA11/@?:\&E'P[]OJ MZQ0D)@VW%,^/M;4CJMK:9M@7<24D%K$-IW_N :R>!66-(,-"Q_/CA9[NK'HF M>%J;HK(U7FN4BP1$SXNBEC[[/90)PH4&KTL\E$OMA6?&-:;F&,Q "$CN-MT^ MZ+*PJ&=2"47-KP)I,SX'NA\"TZ$^!U:_P/I86 ?$S85VP+"%UW$,GIUG)CJ9 MQS*K:IJ+JNK3$GKO**$GT([UQ2"YUG=-IZ+:$3>?V8YA"^_<,7B;V6($%+]BJ,VW)'(&Y;M@A=6]=7.E3N4STB4N%Z1\D.WT=4A_!$9H[KBU+U_9TS S3%X!/H5?5-)=7U:N;;_LM.GH90YB"\G6A/'&:XUWBU=US9EQA#G MQF@832=$T:-O-_=US:6W[]725MOO$ZG_.C+X(ZHN9QVC%I(KNVM MV.%VLXH7F,WAE(>Z]=KF(JOW:\FYN8=RDX*8ZW'XL^!+M=#S?H;9B2\L'0C1 M7(XOVK8X_X-ME,M@+S5WNL"\BKLY8C[,BZ6ZY"]02P$"% ,4 " "@B54 M.T/KT*H0 !;:P #@ @ $ 9#(W-S$V,&0X:RYH=&U0 M2P$"% ,4 " "@B54N1 C#](M U'P0 $0 @ '6$ M9#(W-S$V,&1E>#$P,2YH=&U02P$"% ,4 " "@B54@^X#^DL# !\"P M$0 @ '7/@ &UL4$L! A0#% @ H(E5/T)L@K&! T"P !4 M ( ! TD ')G;',M,C R,3$R,S%?<')E+GAM;%!+!08 !0 % + $ ! #\30 ! end